The effect of oral folinic acid rescue therapy on pemetrexed induced neutropenia and other toxicity: A randomized open-label trial.

When people with certain types of cancer, like non-small cell lung cancer, mesothelioma, or thymoma, receive chemotherapy, they might experience side effects. One common and important side effect is called neutropenia. This means that the treatment causes a drop in a type of white blood cell called neutrophils. These cells are really important for fighting off infections, so having too few of them can make you more likely to get ill.

This study is looking at a medicine called Rescuvolin, which comes in 15mg tablets. We want to see if taking Rescuvolin can help to prevent or reduce this drop in white blood cells. Specifically, we'll be checking how many neutrophils people have in their blood around 8 to 10 days after their cancer treatment. The idea is to see if Rescuvolin can act as a kind of 'rescue therapy' to help protect these important blood cells.

Apart from looking at white blood cell counts, the study will also check for other things. This includes how severe any neutropenia is, levels of a substance in the blood called homocysteine, and how well the cancer treatment is working overall. We'll also keep an eye on whether people need to stop their treatment, or have their doses changed or delayed, as this can sometimes happen due to side effects. By carefully studying all these aspects, we hope to learn if Rescuvolin can make cancer treatment more manageable and safer for patients.